Dupixent Lawsuit

Our law firm is currently evaluating claims for patients who were diagnosed with Cutaneous T-Cell Lymphoma after using the drug Dupixent. While it is an effective treatment for patients with inflammatory conditions, recent studies suggest a link between its use and an increased risk of Cutaneous T-Cell Lymphoma (CTCL), a rare and serious cancer.

If you or a loved one has been diagnosed with Cutaneous T-Cell Lymphoma after using Dupixent, please contact our law firm today as you may be entitled to financial compensation. Contact the Steinberg Law Firm now for a free consultation.

Dupixent T-Cell Lymphoma Lawsuits: What Patients Need to Know

Dupixent has provided relief for millions of patients struggling with eczema, asthma, and other inflammatory conditions. However, mounting evidence suggests this widely prescribed medication may carry a serious hidden risk: an increased chance of developing cutaneous T-cell lymphoma (CTCL), a rare but aggressive form of cancer that primarily affects the skin.

Recent studies have revealed alarming connections between Dupixent use and CTCL development, with some research showing patients face up to 4.5 times higher risk of developing this cancer. These findings have prompted a wave of lawsuits against Dupixent’s manufacturers, Sanofi and Regeneron, as patients claim they were not adequately warned about these potentially life-threatening side effects.